Abstract
We present the long-term follow-up and results of subsequent treatments in patients with chronic lymphocytic leukemia treated initially with cladribine + prednisone or chlorambucil + prednisone in a randomized, cross-over study. We found higher complete and overall responses rates in patients who received cladribine + prednisone as first and second-line treatment but no significant differences in survival.
Publication types
-
Letter
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Chlorambucil / administration & dosage*
-
Cladribine / administration & dosage*
-
Cross-Over Studies
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
-
Middle Aged
-
Prednisone / therapeutic use*
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Chlorambucil
-
Cladribine
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone